SkinBioTherapeutics Plc

SBTX.L · LSE
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income£338-£1,034-£1,541-£1,335
Dep. & Amort.£245£154£123£45
Deferred Tax£0£0£0£0
Stock-Based Comp.£0£0£0£0
Change in WC-£652£86-£152£15
Other Non-Cash-£426-£9£173-£91
Operating Cash Flow-£495-£803-£1,398-£1,365
Investing Activities
PP&E Inv.-£75-£83-£122-£15
Net Acquisitions-£45-£1,417-£2,098£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.£0£0£0-£62
Investing Cash Flow-£121-£1,500-£2,220-£76
Financing Activities
Debt Repay.£0£950£1,472-£20
Stock Issued£4,244£1,812£129£2,991
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.-£85-£22-£22£0
Financing Cash Flow£4,158£2,740£1,578£2,971
Forex Effect£0£0£0£0
Net Chg. in Cash£3,542£436-£2,040£1,529
Supplemental Information
Beg. Cash£1,237£801£2,841£1,312
End Cash£4,779£1,237£801£2,841
Free Cash Flow-£499-£806-£1,411-£1,380